Method of predicting body composition in prepubertal children infected with human immunodeficiency virus

Use of Recombinant Human Activated Protein C to Enhance Viability of Transplant Tissue

The present invention relates to the use of activated Protein C (aPC) to enhance the viability of transplant graft. In certain instances, the invention provides methods of ex vivo perfusion of transplant graft with a composition comprising aPC. 1. A method for improving the viability of transplant graft comprising contacting the transplant graft with a composition comprising at least one selected from the group consisting of activated Protein C (aPC) , an isolated nucleic acid molecule encoding aPC , Protein C (PC) , and an isolated nucleic acid molecule encoding PC.2. The method of claim 1 , wherein the transplant graft is contacted with the composition ex vivo.3. The method of claim 1 , wherein the transplant graft is allogeneic.4. The method of claim 1 , wherein the transplant graft is xenogeneic.5. The method of claim 1 , wherein the transplant graft expresses Endothelial Protein C Receptor (EPCR).6. The method of claim 5 , wherein the transplant graft is from an organism modified to express EPCR.7. The method of claim 1 , wherein the transplant graft is selected from the group consisting of lung claim 1 , heart claim 1 , kidney claim 1 , liver claim 1 , pancreas claim 1 , intestine claim 1 , and multivisceral transplant.8. The method of claim 1 , wherein the method comprises perfusing the transplant graft with the composition.9. The method of claim 1 , wherein the composition comprises a crystalloid perfusate comprising aPC.10. The method of claim 1 , wherein the composition comprises a whole-blood perfusate comprising aPC.11. The method of claim 1 , wherein the method reduces or prevents thrombosis in the transplant graft.12. A method for improving the viability of transplant graft comprising:a.) obtaining transplant graft;b.) contacting the transplant graft with a composition comprising at least one selected from the group consisting of activated Protein C (aPC), an isolated nucleic acid molecule encoding aPC, Protein C (PC), and an isolated nucleic acid ...

BiFET INCLUDING A FET HAVING INCREASED LINEARITY AND MANUFACTURABILITY

According to one exemplary embodiment, a BiFET situated on a substrate comprises an emitter layer segment situated over the substrate, where the emitter layer segment comprises a semiconductor of a first type. The HBT further comprises a first segment of an etch stop layer, where the first segment of the etch stop layer comprises InGaP. The BiFET further comprises a FET situated over the substrate, where the FET comprises source and drain regions, where a second segment of the etch stop layer is situated under the source and drain regions, and where the second segment of the etch stop layer comprises InGaP. The FET further comprises a semiconductor layer of a second type situated under the second segment of the etch stop layer. The etch stop layer increases linearity of the FET and does not degrade electron current flow in the HBT.

Method of predicting body composition in prepubertal children infected with human immunodeficiency virus

A method for predicting fat free mass (FFM) and total body water (TBW) of a prepubertal child infected with human immunodeficiency virus (HIV) comprises the steps of measuring a child's height, measuring the child's total body resistance, and predicting fat free mass (FFM) and total body weight (TBW) of said child using the measured height and total body resistance.

BiFET WITH A FET WITH ENLARGED LINEARITY AND PRODUCTIONABILITY

Treating stress response with chemokine receptor ccr5 modulators

The use of chemokine receptor CCR5 modulators (e.g., CCR5 antagonists) is disclosed for the treatment or prevention of stress response (e.g., fever) in a subject resulting from surgery, infection or other insult to the subject (e.g., a warm-blooded vertebrate). Methods for treating or preventing disorders involving the activation of pro-inflammatory cytokines by administration of a CCR5 modulator, for inhibiting the endogenous production of pro-inflammatory cytokines by the administration of CCR5 modulators, and for determining the efficacy of CCR5 modulators in correcting abnormal levels of pro-inflammatory cytokines are also disclosed.

Treating stress response with chemokine receptor CCR5 modulators

Treating stress response with chemokine receptor ccr5 modulators

The use of chemokine receptor CCR5 modulators (e.g., CCR5 antagonists) is disclosed for the treatment or prevention of stress response (e.g., fever) in a subject resulting from surgery, infection or other insult to the subject (e.g., a warm-blooded vertebrate). Methods for treating or preventing disorders involving the activation of pro-inflammatory cytokines by administration of a CCR5 modulator, for inhibiting the endogenous production of pro-inflammatory cytokines by the administration of CCR5 modulators, and for determining the efficacy of CCR5 modulators in correcting abnormal levels of pro-inflammatory cytokines are also disclosed.

Treating stress response with chemokine receptor CCR5 modulators